non-steroidal anti-inflammatory drugs (NSAIDs) utilized to take care of pain in

non-steroidal anti-inflammatory drugs (NSAIDs) utilized to take care of pain in individuals with sickle cell disease (SCD) are metabolized with the enzyme. on substrate-specific ramifications of version alleles common in populations with hereditary susceptibility to SCD. enzyme continues to be implicated in interindividual variability in analgesic response to NSAIDs [4]. A lot more than 40 allelic variations from the gene have already been discovered ( accessed Apr 12 2014 The regularity from the allelic variations continues to be reported to differ among Caucasian African and Asian populations. The and so are the two typically known alleles to bring about decreased enzyme metabolic activity in varying magnitudes for substrates. However four other minor frequency alleles allelic combinations enzymatic activity and expression levels: poor metabolizers (PMs) intermediate metabolizers (IMs) and extensive metabolizers (EMs). Poor metabolizers are homozygous or compound heterozygous for two reduced function UNC0646 alleles. Intermediate metabolizers carry one functional allele and one UNC0646 reduced function allele but may demonstrate a wide range of levels of enzyme activity. Extensive metabolizers have two functional alleles. Current NSAIDs dosing strategies in children with SCD are based on comparable per kilogram dosing across the pediatric age range [5]. Implicit in this dosing strategy is the assumption that the individual patient is an extensive metabolizer. However differences in metabolic activity of allelic variants of the enzyme may lead to differences in NSAIDs dose effect particularly adverse effects in patients with deficient metabolic phenotypes [6]. Gastrointestinal complications renal impairment fluid retention UNC0646 and exacerbation of asthma are some of the adverse effects associated with impaired NSAIDs metabolism. To our knowledge no study has investigated the frequency of pharmacologically relevant allelic variants of the enzymes and their implications for NSAIDs therapy in SCD patients which is the aim of this pilot study. METHODS Human subjects The study participants were pediatric patients with SCD receiving care at the Georgia Regents University Comprehensive Sickle Cell Center pediatric clinic. The study was approved by the Georgia Regents University Institutional Review Board. Written informed consent UNC0646 was obtained from each patient’s parent or legal guardian. Each patient also provided written assent. Study participants were recruited between January 2011 and May 2011. UNC0646 CYP2C9 genotyping Whole blood samples (10 ml in tubes containing EDTA) were collected from the patients in steady state. Genomic DNA was extracted using the Puregene? DNA Purification Kit (Qiagen CA USA) according to the manufacturer’s instructions. The allele designations UNC0646 refer to those defined by the Cytochrome P450 Allele Nomenclature Committee [7]. Nine alleles and *alleles *and *and *alleles were amplified by PCR and interrogated using RFLP assays as previously described [8]. and *were amplified using exon 2/3 primers and *was amplified using exon 7 primers as previously described [8].The wild-type allele was assigned in the absence of other detectable variant alleles. Statistical analysis allele frequencies were presented with 95% confidence interval. Genotype frequencies were presented as percentage of the study cohort with 95% confidence interval. The observed genotype frequencies were compared with those expected for concordance with Hardy-Weinberg equilibrium using the X2 test. RESULTS The study participants’ demographic features and clinical characteristics are summarized in Table I. Thirty (13 males and 17 females) African Rabbit Polyclonal to Aggrecan (Cleaved-Asp369). American pediatric SCD patients were enrolled in the study. Race was self-reported by either parent or study participant. The age of the participants ranged from 7-17 years. Nineteen study participants (63.3%) were prescribed hydroxyurea. In terms of treatment of SCD hydroxyurea is the only FDA approved drug and has been associated with decreased frequency of VOC and morbidity [3]. The allele and genotype frequencies for the study cohort are listed in Table II. We surveyed nine alleles (*1 and In our cohort the wild type.